This is a summary of the European public assessment report (EPAR) for Rekovelle. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rekovelle. For practical information about using Rekovelle, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.
Therapeutic Area (MeSH)
N/AATC Code
G03GA10
ATC Item
follitropin delta
Pharmacotherapeutic Group
Sex hormones and modulators of the genital system
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| follitropin delta | N/A | 重组人促卵泡激素 |
EMA Name
Rekovelle
Medicine Name
Rekovelle
Aliases
N/ANo risk management plan link.
